{"disease":{"id":"condition","name":"condition"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"omeprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"omeprazole","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to other conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"campath","indication_name":"Conditioning treatment prior to allogeneic haematopoietic stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"algeldrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"ALGELDRATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"algeldrate","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"prevacid","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"esomeprazole","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pantoprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"carbaldrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"carbaldrate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"carbaldrate","quality_score":null,"revenue":null,"mechanism":"Carbaldrate works by reducing stomach acid production."},{"drug_id":"almasilate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gelusil","generic_name":"ALMASILATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"almasilate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"alum","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Alum","generic_name":"Alum","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"protonix-iv","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of eye conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of psychiatric conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of cardiovascular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of respiratory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of gastrointestinal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of genitourinary conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of musculoskeletal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of dermatological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of allergic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of immunological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of infectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of parasitic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of fungal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of viral conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of bacterial conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of prion conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of amyloid conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"aciphex","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"rabeprazole-40-mg","indication_name":"Pathological Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"alemtuzumab","indication_name":"Conditioning treatment prior to allogeneic haematopoietic stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rabeprazol","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"omeprazol","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omeprazol","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"loteprednol-etabonate","indication_name":"Steroid-responsive inflammatory conditions of the eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lansoprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"n-acetyltyrosine","indication_name":"Nutritional support in stress conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"N-Acetyl-Tyrosine","generic_name":"N-Acetyltyrosine","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Amino Acid [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"orphenadrine","indication_name":"Acute painful musculoskeletal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1219","indication_name":"Treatment of Pathological Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RABEPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"fluorometholone-acetate","indication_name":"Steroid-responsive inflammatory conditions of the eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flarex","generic_name":"FLUOROMETHOLONE ACETATE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Steroid-responsive inflammatory ocular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Inflammatory conditions of the palpebral and bulbar conjunctiva","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"hydroxyzine-pamoate","indication_name":"Management of pruritus due to allergic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYZINE PAMOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"25-mg-sodium-hyaluronate-go-on","indication_name":"Condition as directed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"25 mg sodium hyaluronate \"GO ON\"","company_name":"Khon Kaen University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"bacillus-subtilis","indication_name":"Skin and Lung Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bacillus subtilis","company_name":"DreamTec Research Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"bacillus-subtilis","indication_name":"Other Internal Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bacillus subtilis","company_name":"DreamTec Research Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"dexrabeprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"dexrabeprazole","indication_name":"Pathological Gastric Hypersecretory Condition","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"sodium-citrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bss","generic_name":"SODIUM CITRATE","company_name":"B Braun","drug_phase":"marketed","molecular_target":"Calcium","drug_class":"sodium citrate","quality_score":51,"revenue":null,"mechanism":"ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade."},{"drug_id":"magnesium-silicate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"MAGNESIUM SILICATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium silicate","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"magnesium-carbonate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"MAGNESIUM CARBONATE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"magnesium-hydroxide","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Milk of Magnesia","generic_name":"magnesium hydroxide","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Gastric acid (direct neutralization) + osmotic effect in intestine","drug_class":"Osmotic laxative, Antacid","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ranitidine","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"3-7","indication_name":"Condition listed above or as directed by the physician","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silicea","generic_name":"\"3+7\"","company_name":"Unique","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."}],"pipeline":[],"offLabel":[],"totalMarketed":278,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06617533","title":"Evaluation of the Primary Care First Model","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25000000,"lead_sponsor_name":"Mathematica Policy Research, Inc.","has_results":false},{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT05745688","title":"Gender Bias and Overtreatment in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":1048000,"lead_sponsor_name":"Universidad Miguel Hernandez de Elche","has_results":false},{"nct_id":"NCT06359587","title":"Re-Purposing the Ordering of Routine Laboratory Tests in Hospitals in British Columbia","phase":"NA","overall_status":"RECRUITING","enrollment_count":700000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05097066","title":"Patterns and Outcomes of Neurosurgery in England Over a Five-year Period","phase":"","overall_status":"COMPLETED","enrollment_count":371418,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT06420453","title":"How Long Can Labor Last? Person Centred Care During Labor to Increase Safety for Women and Newborn","phase":"","overall_status":"COMPLETED","enrollment_count":300000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06623799","title":"Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"QHSLab, Inc.","has_results":false},{"nct_id":"NCT03353389","title":"Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang","phase":"","overall_status":"COMPLETED","enrollment_count":170000,"lead_sponsor_name":"Selayang Hospital","has_results":false},{"nct_id":"NCT04459793","title":"The Danish Occupational Medicine Cohort - Long-term Prognosis for Patients With Work-related Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":145521,"lead_sponsor_name":"Regional Hospital West Jutland","has_results":false},{"nct_id":"NCT06784713","title":"DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN","phase":"","overall_status":"COMPLETED","enrollment_count":127277,"lead_sponsor_name":"University of Tartu","has_results":false},{"nct_id":"NCT05013944","title":"AnovaOS Network Powered Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Anova Enterprises, Inc","has_results":false},{"nct_id":"NCT04182503","title":"Environmental Factors and Embryonic Development Project","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT04187729","title":"Precision Genomics Medicine Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":false},{"nct_id":"NCT05952271","title":"Herpes Zoster Hospitalizations in Italy","phase":"","overall_status":"UNKNOWN","enrollment_count":72000,"lead_sponsor_name":"University of L'Aquila","has_results":false},{"nct_id":"NCT03911687","title":"(CONCERN) Clinical Decision Support (CDS) System","phase":"NA","overall_status":"COMPLETED","enrollment_count":60893,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT05376059","title":"How v. How and Why Nudges and Rewards","phase":"NA","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"RIVER Foundation","has_results":false},{"nct_id":"NCT01837693","title":"Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2","phase":"NA","overall_status":"COMPLETED","enrollment_count":41127,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT06583694","title":"Bangkok Noi District Electronic Health Database With Socioeconomic Factors From Bangkok Noi Model Project (BANMOP)","phase":"","overall_status":"COMPLETED","enrollment_count":21286,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT07473466","title":"Evaluation of Reminder Strategies (Emails and Text Messages) to Increase Participation in the Le French Gut E-cohort","phase":"NA","overall_status":"COMPLETED","enrollment_count":20487,"lead_sponsor_name":"SKEZI","has_results":false},{"nct_id":"NCT04827615","title":"Evaluation of the Ambuja Cement Foundation Noncommunicable Disease Program in Bathinda District of Punjab, India","phase":"NA","overall_status":"COMPLETED","enrollment_count":11322,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT04717349","title":"Data Collection Study of Pediatric and Adolescent Gynecology Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04017273","title":"Older Emergency Department Users and Hospitalization After an Index Visit: Results of ER2 Database","phase":"","overall_status":"UNKNOWN","enrollment_count":10971,"lead_sponsor_name":"Jewish General Hospital","has_results":false},{"nct_id":"NCT04706481","title":"Archival of Human Biological Samples in CU-Med Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06476470","title":"Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT05952999","title":"Analysis of the Virtual Acute Care at Home Experience","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9654,"lead_sponsor_name":"OSF Healthcare System","has_results":false},{"nct_id":"NCT01568658","title":"Genetic and Physical Study of Childhood Nerve and Muscle Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":9300,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT00625066","title":"Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy","phase":"","overall_status":"COMPLETED","enrollment_count":8108,"lead_sponsor_name":"Vanderbilt University","has_results":false},{"nct_id":"NCT00128661","title":"Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7466,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06395675","title":"Clinical Evaluation of the ID NOW™ CT/NG Test","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":7100,"lead_sponsor_name":"Abbott Rapid Dx","has_results":false},{"nct_id":"NCT07215897","title":"Evaluating Covered California's Grocery Support Program","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6975,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07112729","title":"Effectiveness of SMS Invitation on Colorectal Cancer Screening on 45-49-Year-Olds","phase":"NA","overall_status":"COMPLETED","enrollment_count":6708,"lead_sponsor_name":"Chang Gung University","has_results":false},{"nct_id":"NCT06782776","title":"Role of Doppler Echoflowmetry to Define Risk Factors for the Development of Complications in Twin Pregnancies","phase":"","overall_status":"RECRUITING","enrollment_count":6600,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04367740","title":"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":6313,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT07049861","title":"Advancing Biopsychosocial Care Training Initiative","phase":"NA","overall_status":"RECRUITING","enrollment_count":6200,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04006990","title":"The Bed Rest Avoidance Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":6089,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06527703","title":"An International Prospective, Observational, Multi-centre Study on the Duration of Pre-operative Liquid Fasting","phase":"","overall_status":"COMPLETED","enrollment_count":5100,"lead_sponsor_name":"Mater Dei Hospital, Malta","has_results":false},{"nct_id":"NCT02993120","title":"Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":5006,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05367115","title":"Verification of the Epidemiology and Mortality of Rare Diseases in Taiwan With Real-world Evidence","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT06799988","title":"NutFinForce: The Impact of Digitally Delivered Lifestyle Performance Medicine Intervention on Defense Performance in Finland","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Helsinki","has_results":false},{"nct_id":"NCT07477197","title":"Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT04065620","title":"Ambulatory Blood Pressure in HFPEF Outcomes Global Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT03626389","title":"Clinical Course of Patients Receiving Physiotherapy Services in Primary Health Care","phase":"","overall_status":"COMPLETED","enrollment_count":4985,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT00666731","title":"Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":4945,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT03313583","title":"French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":4720,"lead_sponsor_name":"Etablissement Français du Sang","has_results":false},{"nct_id":"NCT05289206","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4446,"lead_sponsor_name":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","has_results":false},{"nct_id":"NCT05492240","title":"Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities","phase":"NA","overall_status":"COMPLETED","enrollment_count":4383,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05240742","title":"CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication","phase":"","overall_status":"COMPLETED","enrollment_count":4291,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT05976126","title":"Characterization of a Population Living in Highly Contaminated Settlement in Campania Region","phase":"","overall_status":"COMPLETED","enrollment_count":4227,"lead_sponsor_name":"Francesca De Filippis","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}